

Supplementary Table 1. *BRIP1* variants called in SEARCH

Exon	Nucleotide change	Protein change	dbSNP ID	CASES (n=13,213)		CONTROLS (n=5242)		Validated with Sanger? ¹	<i>In silico</i> tools		
				Het.	Hom.	Het.	Hom.		CADD	PolyPhen	SIFT
Truncating Variants											
3	c.133G>T	p.Glu45Ter		0	0	1	0	Y	37	-	-
	c.380-1G>T			1		0		N/D	17.99	-	-
5	c.394dupA	p.Thr132AsnfsTer10		0		1		Y	19.7	-	-
7	c.633delT	p.Gly212AlafsTer62		1		0		N/D	16.8	-	-
7	c.890delA	p.Lys297SerfsTer6		1		0		Y	32	-	-
8	c.1056T>G	p.Tyr352Ter		1	0	0	0	Y	39	-	-
9	c.1315C>T	p.Arg439Ter		1	0	0	0	Y	40	-	-
13	c.1871C>A	p.Ser624Ter		1	0	0	0	Y	43	-	-
13	c.1888dupA	p.Thr630AsnfsTer9		1		1		Y	24.7	-	-
14	c.2010dupT	p.Glu671Ter		4		1		Y	29.3	-	-
14	c.2038_2039dupTT	p.Leu680PhefsTer9		1		0		N	16.54	-	-
14	c.2050_2051delTG	p.Cys684ProfsTer32		1		0		Y	23.7	-	-
19	c.2684_2687delCCAT	p.Ser895Ter		1		1		Y	35	-	-
19	c.2715dupT	p.Glu906Ter		1		0		Y	16.22	-	-
19	c.2765T>G	p.Leu922Ter		1	0	0	0	Y	37	-	-
	c.2906-2A>C			4		2		N/D	15.83	-	-
20	c.2990_2993delCAAA	p.Thr997ArgfsTer61		1		0		N/D	34	-	-
20	c.2992_2993delAA	p.Lys998GlufsTer3		1		4		Y	38	-	-
20	c.3401delC	p.Pro1134LeufsTer16		2		1		N/D	41	-	-
20	c.3525dupT	p.Ile1176TyrfsTer13		1		0		Y	16.33	-	-
20	c.3651G>A	p.Trp1217Ter		0	0	1	0	Y	38	-	-
In-frame deletion											
20	c.3374_3376delCAG	p.Ala1125del		0		2		N/D	16.11		

Missense Variants											
3	c.139C>G	p.Pro47Ala	rs28903098	13	0	5	0	N/D	14.21	prob. damaging	tolerated
3	c.169C>T	p.Leu57Phe		1	0	0	0	N/D	12.46	prob. damaging	deleterious
3	c.205G>A	p.Gly69Arg	rs372581879	0	0	1	0	N/D	15.08	benign	tolerated
4	c.293A>G	p.Asn98Ser		0	0	1	0	N/D	0.013	benign	tolerated
4	c.316C>T	p.Arg106Cys		1	0	1	0	N/D	11.58	benign	tolerated
4	c.317G>A	p.Arg106His	rs143615668	1	0	0	0	N/D	8.081	benign	tolerated
5	c.413T>C	p.Leu138Ser		1	0	2	0	Y	23.1	poss. damaging	deleterious
5	c.415T>G	p.Ser139Ala	rs202072866	1	0	0	0	Y	23.9	poss. damaging	tolerated
5	c.430G>A	p.Ala144Thr	rs116952709	3	0	1	0	N/D	18.56	poss. damaging	tolerated
6	c.517C>T	p.Arg173Cys	rs4988345	121	22	45	6	Y	20.8	Benign	deleterious
6	c.538G>C	p.Val180Leu		0	0	1	0	N/D	11.10	Benign	tolerated
6	c.543C>A	p.His181Gln		1	0	0	0	N/D	0.052	Benign	tolerated
6	c.550G>T	p.Asp184Tyr	rs201047375	6	0	2	0	N/D	12.95	prob. damaging	deleterious
6	c.577G>A	p.Val193Ile	rs4988346	111	18	42	5	N/D	0.342	Benign	tolerated
6	c.590C>A	p.Ser197Tyr		0	1	1	0	N/D	9.206	poss. damaging	tolerated
6	c.590C>T	p.Ser197Phe		0	1	0	0	N/D	10.27	Benign	tolerated
7	c.668A>G	p.Gln223Arg		2	0	0	0	N/D	10.71	Benign	tolerated
7	c.679C>G	p.Gln227Glu	rs45459799	2	0	1	0	N/D	0.156	Benign	tolerated
7	c.751C>T	p.Arg251Cys		1	0	0	0	Y	21.6	prob. damaging	deleterious
7	c.764A>G	p.Gln255Arg		1	0	0	0	N/D	19.31	prob. damaging	deleterious
7	c.778A>G	p.Thr260Ala	rs138743097	3	0	2	0	N/D	11.43	benign	tolerated
7	c.790C>T	p.Arg264Trp	rs28997569	27	0	19	0	Y	16.72	prob. damaging	deleterious
7	c.797C>T	p.Thr266Met		0	0	1	0	Y	21.4	prob. damaging	deleterious
7	c.841C>A	p.His281Asn		1	0	0	0	N/D	17.64	poss. damaging	tolerated
7	c.856C>T	p.Pro286Ser		0	0	1	0	N/D	16.49	prob. damaging	tolerated
7	c.868G>A	p.Gly290Ser	rs145601931	1	0	0	0	N/D	5.895	benign	tolerated
7	c.888G>C	p.Glu296Asp		0	0	1	0	N/D	11.59	poss. damaging	tolerated
7	c.890A>G	p.Lys297Arg	rs28997570	49	0	25	0	N/D	8.669	benign	tolerated
8	c.931T>C	p.Tyr311His		1	0	0	0	N/D	9.222	benign	tolerated
8	c.941A>G	p.His314Arg	rs112076926	2	0	0	0	N/D	19.09	prob. damaging	tolerated
8	c.1000G>A	p.Ala334Thr		2	0	0	0	Y	33	prob. damaging	deleterious
8	c.1012G>A	p.Glu338Lys		1	0	0	0	Y	33	prob. damaging	deleterious
8	c.1021G>A	p.Val341Ile		1	0	0	0	N/D	19.25	benign	deleterious
8	c.1045G>C	p.Ala349Pro	rs149364097	1	0	1	0	Y	17.53	poss. damaging	deleterious

8	c.1054T>C	p.Tyr352His		1	0	1	0	Y	18.42	poss. damaging	deleterious
8	c.1055A>G	p.Tyr352Cys	-	1	0	0	0	Y	20.8	prob. damaging	deleterious
8	c.1105T>C	p.Tyr369His	-	1	0	0	0	Y	23.0	prob. damaging	deleterious
8	c.1114C>T	p.Leu372Phe	-	2	0	0	0	Y	21.4	prob. damaging	deleterious
8	c.1124C>T	p.Ala375Val	-	1	0	0	0	N/D	19.22	benign	deleterious
9	c.1207C>T	p.Arg403Trp	rs369631413	0	0	1	0	Y	19.28	prob. damaging	deleterious
9	c.1216G>T	p.Ala406Ser	-	1	0	0	0	N/D	20.6	poss. damaging	deleterious
9	c.1255C>T	p.Arg419Trp	rs150624408	4	0	2	0	Y	20.6	prob. damaging	deleterious
9	c.1286A>C	p.Asn429Thr	-	0	0	1	0	Y	19.17	prob. damaging	tolerated
9	c.1292G>A	p.Arg431Lys	-	1	0	0	0	N/D	21.5	poss. damaging	tolerated
12	c.1637A>G	p.Asp546Gly	-	1	0	1	0	N/D	18.40	benign	deleterious
12	c.1652C>T	p.Ala551Val	rs375246789	2	0	0	0	N/D	23.7	prob. damaging	tolerated
12	c.1655T>C	p.Ile552Thr	rs369340666	1	0	1	0	Y	22.5	poss. damaging	deleterious
12	c.1660C>G	p.Gln554Glu	-	1	0	0	0	N/D	16.31	poss. damaging	deleterious
12	c.1676C>G	p.Thr559Arg	-	1	0	0	0	N/D	13.04	poss. damaging	tolerated
12	c.1684A>G	p.Ile562Val	rs45533636	0	0	1	0	N/D	3.237	benign	tolerated
12	c.1704T>G	p.Asn568Lys	-	2	0	0	0	N/D	5.134	benign	tolerated
12	c.1735C>T	p.Arg579Cys	rs28997571	2	0	1	0	N/D	19.23	benign	deleterious
12	c.1759C>G	p.His587Asp	-	0	0	2	0	N/D	13.68	benign	tolerated
12	c.1771T>A	p.Phe591Ile	-	2	0	0	0	N/D	26.0	prob. damaging	tolerated
13	c.1796C>T	p.Ala599Val	-	1	0	0	0	N/D	21.8	prob. damaging	tolerated
13	c.1804G>T	p.Asp602Tyr	-	1	0	0	0	Y	22.0	prob. damaging	deleterious
13	c.1871C>T	p.Ser624Leu		1	0	0	0	Y	32	prob. damaging	deleterious
13	c.1899C>G	p.Ile633Met	rs28997572	3	0	1	0	Y	15.89	prob. damaging	deleterious
14	c.1964C>G	p.Pro655Arg	-	2	0	0	0	Y	26.6	prob. damaging	deleterious
14	c.2071A>C	p.Ile691Leu	-	1	0	0	0	N/D	14.59	poss. damaging	deleterious
14	c.2087C>T	p.Pro696Leu	rs147755155	6	0	0	0	N/D	15.37	prob. damaging	deleterious
15	c.2167G>A	p.Val723Ile	rs145616741	1	0	0	0	N/D	14.99	prob. damaging	tolerated
15	c.2172T>G	p.Ile724Met	-	1	0	0	0	N/D	11.67	prob. damaging	tolerated
15	c.2220G>T	p.Gln740His	rs45589637	20	0	6	0	N/D	10.44	poss. damaging	deleterious
15	c.2221G>T	p.Val741Leu	-	1	0	1	0	N/D	11.22	benign	tolerated
15	c.2233G>A	p.Ala745Thr		2	0	0	0	N/D	15.00	prob. damaging	tolerated
15	c.2236A>G	p.Ile746Val	rs111536363	2	0	0	0	N/D	11.46	benign	tolerated
16	c.2285G>A	p.Arg762His	rs200960251	1	0	0	0	N/D	15.93	prob. damaging	deleterious
16	c.2330G>A	p.Arg777His		2	0	0	0	N/D	16.54	prob. damaging	deleterious

16	c.2344A>G	p.Ile782Val	rs142806416	3	0	1	0	N/D	11.36	benign	tolerated
17	c.2440C>T	p.Arg814Cys	rs201869624	1	0	0	0	Y	19.51	prob. damaging	deleterious
17	c.2441G>A	p.Arg814His	rs45468199	2	0	0	0	N/D	15.43	benign	tolerated
18	c.2542C>T	p.Arg848Cys	rs45572934	0	0	1	0	Y	23.6	prob. damaging	deleterious
18	c.2561G>A	p.Ser854Asn	-	1	0	0	0	N/D	1.534	benign	tolerated
18	c.2564G>A	p.Arg855His	rs200894063	1	0	0	0	Y	19.48	poss. damaging	deleterious
19	c.2623G>C	p.Glu875Gln	-	0	0	1	0	N/D	12.82	poss. damaging	tolerated
19	c.2666A>G	p.Gln889Arg	-	1	0	0	0	N/D	10.85	benign	tolerated
19	c.2717A>G	p.Glu906Gly	-	0	0	1	0	N/D	5.913	benign	tolerated
19	c.2723C>T	p.Thr908Ile	-	1	0	0	0	N/D	1.648	benign	tolerated
19	c.2755T>C	p.Ser919Pro	rs4986764	6348	4816	2474	1942	N/D	4.321	benign	tolerated
19	c.2863A>C	p.Asn955His	-	1	0	0	0	N/D	7.268	benign	tolerated
20	c.2935A>G	p.Lys979Glu	-	3	0	0	0	N/D	6.269	benign	tolerated
20	c.2948T>A	p.Ile983Asn	-	0	0	1	0	N/D	8.314	benign	tolerated
20	c.3050C>T	p.Pro1017Leu	-	3	0	2	0	N/D	0.119	benign	tolerated
20	c.3064G>A	p.Glu1022Lys	-	4	0	7	0	N/D	1.051	benign	tolerated
20	c.3103C>T	p.Arg1035Cys	rs45437094	1	0	0	0	N/D	7.694	benign	deleterious
20	c.3178G>A	p.Val1060Ile	rs149016505	1	0	0	0	N/D	6.966	benign	tolerated
20	c.3236T>C	p.Ile1079Thr	rs150813402	1	0	0	0	N/D	3.250	benign	tolerated
20	c.3275C>T	p.Pro1092Leu	-	1	0	0	0	N/D	0.003	benign	tolerated
20	c.3290A>C	p.Glu1097Ala	-	1	0	1	0	N/D	10.58	benign	deleterious
20	c.3378A>C	p.Glu1126Asp	rs145855459	3	0	0	0	Y	13.91	benign	tolerated
20	c.3444C>A	p.Asp1148Glu	rs28997573	7	0	10	0	Y	0.005	benign	tolerated
20	c.3448G>C	p.Ala1150Pro	-	1	0	0	0	N/D	5.508	benign	tolerated
20	c.3487G>A	p.Asp1163Asn	-	1	0	0	0	Y	0.021	benign	tolerated
20	c.3493A>C	p.Ile1165Leu	-	1	0	0	0	N/D	3.169	benign	tolerated
20	c.3507C>A	p.Asp1169Glu	rs375741316	2	0	0	0	N/D	5.323	benign	tolerated
20	c.3571A>G	p.Ile1191Val	-	1	0	0	0	N/D	0.234	benign	tolerated
20	c.3621T>A	p.Asp1207Glu	-	1	0	0	0	N/D	8.997	benign	tolerated

¹N/D = no validation attempted.

Supplementary Table 2. *BRIP1* variants called in BCFR

Exon	Nucleotide change	Protein change	dbSNP ID	CASES (n=1,313)	CONTROLS (n=1,123)	Validated with Sanger?	CADD	PolyPhen	SIFT
Truncating Variants									
14	c.2008insT	p.Glu671Ter	-	0	1	Yes	32		
15	c.2108delAinsTCC	p.Lys703fs		1	0	Yes	16.77		
17	c.2392C>T	p.Arg798Ter	rs137852986	2	1	Yes	39		
20	c.2992del4, c.2992_2995del	p.Lys998fs (Lys998Glufs*60)		1	0	Yes	36		
Missense Variants									
2	c.10A>G	p.Met4Val	rs45512093	1	0	Yes	1.235	benign	tolerated
3	c.139C>G	p.Pro47Ala	rs28903098	0	4	Yes	14.21	prob. damaging	deleterious
4	c.254C>T	p.Ser85Leu		1	0	Yes	13.95	poss. damaging	tolerated
4	c.316C>A	p.Ar106Ser		0	1	Yes	5.990	benign	tolerated
5	c.430G>A	p.Ala144Thr		8	1		18.56	prob. damaging	tolerated
6	c.587A>G	p.Asn196Ser		3	1	Yes	0.036	benign	tolerated
6	c.590C>T	p.Ser197Phe		1	0	Yes	10.27	prob. damaging	tolerated
7	c.689C>T	p.Ser230Leu		0	1	Yes	3.213	benign	tolerated
7	c.790C>T	p.Arg264Trp	rs28997569	0	1	Yes	16.72	prob. damaging	deleterious
7	c.890A>G	p.Lys297Arg	rs28997570	3	9	Yes	8.669	poss. damaging	tolerated
8	c.975A>T	p.Leu325Phe		0	1	Yes	12.60	benign	deleterious
10	c.1376G>C	p.Arg459Thr		0	1	Yes	14.03	benign	tolerated
11	c.1499A>G	p.Lys500Arg		1	0	Yes	14.65	prob. damaging	tolerated
12	c.1735C>T	p.Arg579Cys	rs28997571	0	1	Yes	19.23	benign	tolerated
15	c.2220G>T	p.Gln740His	rs45589637	0	2	Yes	10.44	prob. damaging	tolerated
15	c.2236A>G	p.Ile746Val	rs111536363	1	1	Yes	11.46	benign	tolerated

15	c.2254A>C	p.Lys752Gln		1	0	Yes	12.04	prob. damaging	tolerated
16	c.2344A>G	p.Ile782Val	rs142806416	1	0	Yes	11.36	benign	tolerated
19	c.2594G>A	p.Arg865Gln	-	0	1	Yes	28.5	prob. damaging	deleterious
19	c.2830C>G	p.Gln944Glu	rs140233356	1	0	Yes	9.684	poss. damaging	tolerated
20	c.2915T>G	p.Val972Gly	-	1	0	Yes	3.520	benign	tolerated
20	c.2948T>A	p.Ile983Asn	-	1	0	Yes	8.314	benign	tolerated
20	c.3038C>T	p.Thr1013Ile	-	0	1	Yes	10.14	poss. damaging	tolerated
20	c.3392A>C	p.Tyr1131Ser	-	0	1	Yes	13.23	prob. damaging	tolerated
20	c.3464G>A	p.Gly1155Glu	rs45603843	1	0	Yes	0.052	benign	tolerated
20	c.3559G>A	p.Ala1187Thr	rs367610893	1	0	Yes	7.277	benign	tolerated

Supplementary Table 3. *BRIP1* variants called in the PeterMac Study

Exon	Nucleotide change	Protein change	dbSNP ID	CASES (n=1853)	CONTROLS (n=2001)	Validated with Sanger?	CADD	PolyPhen	SIFT
Truncating Variants									
	c.1850A>T	p.Leu617Ter		0	1	yes	43		
13	c.1871C>A	p.Ser624Ter		1	0	yes	43		
17	c.2392C>T	p.Arg798Ter	rs137852986	4	0	yes	39		
20	c.2990_2993delCAAA	p.Thr997ArgfsTer61		0	2	yes	34		
20	c.2992_2993delAA	p.Lys998GlufsTer3		1	1	yes	38		
Missense Variants									
3	c.139C>G	p.Pro47Ala	rs28903098	2	0	N/A	14.21	prob. damaging	deleterious
4	c.347C>G	p.Ser116Cys	.	0	1	yes	15.54	prob. damaging	deleterious
5	c.430G>A	p.Ala144Thr	rs116952709	2	0	N/A	18.56	prob. damaging	tolerated
6	c.517C>T	p.Arg173Cys	rs4988345	33	26	N/A	20.80	prob. damaging	deleterious
6	c.550G>T	p.Asp184Tyr	rs201047375	1	0	N/A	12.95	prob. damaging	deleterious
7	c.790C>T	p.Arg264Trp	rs28997569	2	4	N/A	16.72	prob. damaging	deleterious
8	c.1000G>T	p.Ala334Ser	.	1	0	yes	20.90	benign	deleterious
8	c.1105T>C	p.Tyr369His	.	0	1	yes	23.00	prob. damaging	deleterious
9	c.1168G>A	p.Val390Ile	.	0	1	yes	12.02	benign	tolerated
9	c.1255C>T	p.Arg419Trp	rs150624408	2	0	N/A	20.60	prob. damaging	deleterious
9	c.1286A>C	p.Asn429Thr	.	0	1	yes	19.17	prob. damaging	tolerated
10	c.1433A>G	p.His478Arg	rs45501097	1	0	yes	11.00	benign	tolerated
10	c.1441G>T	p.Gly481Cys	.	1	0	yes	19.52	prob. damaging	deleterious
10	c.1444A>G	p.Ile482Val	rs142744352	0	1	N/A	17.96	prob. damaging	tolerated
11	c.1610T>A	p.Leu537His	.	1	0	yes	20.50	prob. damaging	deleterious
13	c.1798T>C	p.Phe600Leu	.	0	1	yes	24.70	prob. damaging	deleterious
14	c.2056A>G	p.Thr686Ala	.	1	0	yes	12.95	benign	tolerated
14	c.2087C>T	p.Pro696Leu	rs147755155	0	1	N/A	15.37	prob. damaging	deleterious
15	c.2220G>T	p.Gln740His	rs45589637	2	3	N/A	10.44	poss. damaging	deleterious
16	c.2330G>A	p.Arg777His	.	1	0	yes	16.54	prob. damaging	deleterious
17	c.2390A>G	p.Lys797Arg	.	1	0	yes	19.53	prob. damaging	deleterious
17	c.2411A>G	p.His804Arg	.	1	0	yes	20.80	prob. damaging	tolerated

17	c.2440C>T	p.Arg814Cys	rs201869624	1	1	yes	19.51	prob. damaging	deleterious
17	c.2467A>G	p.Arg823Gly	.	1	0	yes	20.80	prob. damaging	deleterious
19	c.2582C>G	p.Ser861Cys	.	1	0	N/A	21.50	prob. damaging	deleterious
20	c.3371A>G	p.Glu1124Gly	.	1	0	N/A	15.13	benign	deleterious
21	c.3505G>T	p.Asp1169Tyr	.	1	0	yes	11.40	poss. damaging	deleterious

N/A – not applicable because no validation done for known variants

Supplementary Table 4. Variants across the *BRIP1* region used to define haplotypes.

Marker	Name	Position	Minor Allele Frequency	Allele1	Allele2
1	rs2188728	59676854	0.423	C	A
2	rs1974491	59724501	0.350	A	G
3	rs7222964	59726936	0.117	A	G
4	rs1858990	59735821	0.164	C	A
5	rs2106664	59736794	0.468	A	G
6	rs7219555	59740122	0.293	A	C
7	rs12603617	59745599	0.241	G	A
8	rs17533380	59746759	0.239	G	A
9	rs4986764	59763347	0.420	G	A
10	rs4986765	59763465	0.343	G	A
11	rs6504063	59767501	0.421	A	G
12	rs11871134	59775949	0.034	A	G
13	rs7214703	59785060	0.340	G	A
14	rs9901948	59793232	0.0001	A	G
15	p.Arg798Ter	59793412	0.0002	G	A
16	rs16945572	59800001	0.079	A	G
17	rs6504066	59802506	0.239	A	G
18	rs2159451	59812748	0.338	G	A
19	rs11652980	59817082	0.050	G	C
20	rs2159450	59826625	0.247	A	C
21	rs2109255	59826765	0.247	A	G
22	rs2191247	59828023	0.248	A	C
23	rs2191249	59835864	0.247	C	A
24	rs9902995	59841185	0.247	A	G
25	rs7212172	59869081	0.246	A	G
26	rs1468577	59870617	0.248	G	A
27	rs2191248	59876352	0.348	G	A
28	rs16945638	59886310	0.078	A	G

29	rs16945643	59893990	0.078	A	G
30	rs7215784	59894708	0.242	G	A
31	rs12453935	59897455	0.197	G	A
32	rs6504074	59899790	0.261	C	A
33	rs16945665	59911493	0.038	G	A
34	rs7222876	59911541	0.001	G	A
35	rs2378908	59911765	0.138	G	A
36	rs7223243	59911799	0.430	G	A

Supplementary Table 5. Published studies of *BRIP1* mutation screening in breast/ovarian cancer families

Authors/Title	Source country / Ethnicity	Study design	Mutation detection method	Selection of cases	Number of cases screened for <i>BRIP1</i> mutations	Number of heterozygous cases	Number of controls screened for <i>BRIP1</i> mutations	Number of heterozygous controls	Comment
Rutter et al Hum Mutat. 2003 Aug;22(2):121-8.	USA	Candidate gene approach	DHPLC and Sanger sequencing	HBOC families + early onset BC cases (<35 y.o)	79	8	30	4	
Lewis et al Breast Cancer Res. 2005;7(6):R1005-16.	Australian	Candidate gene approach; mutation screening of familial BC cases and genotyping of 2 specific missense p.P47A and p.M299I.	DHPLC and Sanger sequencing	Multiple-case BC families (KConFab)	75 families screened for entire coding sequence + 253 index cases screened for exons 3 and 7	1 frameshift, 4 missense	(genotyped only for variants found in cases)	1 missense	
Vahteristo et al BMC Cancer. 2006 Jan 24;6:19.	Finnish	Candidate gene approach; mutation screening of familial BC cases and genotyping of 2 specific missense p.Val93Ile and the SNP ser919Pro.	CSGE	BC families negative for <i>BRCA1/2</i>	43	1 rare missense (Val93Ile)	183 (only genotyped for p.Val93Ile)	0	p.Val93Ile identified in 1 family then genotyped in 346 additional BC cases and in 183 controls
Seal et al Nat Genet. 2006 Nov;38(11):1239-41.	UK	Candidate gene approach with focus on LOF variants; case-control mutation screening study	CSGE	HBOC families	1,212	9	2,081	2	RR 2.0 (95%CI 1.2-3.2)
Guénard et al . J Hum Genet. 2008;53(7):579-91.	French Canadian	Candidate gene approach; likely deleterious variants subsequently genotyped in 73 controls	Sanger sequencing	HBOC families negative for <i>BRCA1/2</i>	96	0	0	N/A	
De Nicolo et al Clin Cancer Res. 2008 Jul 15;14(14):4672-80.	Italian	Candidate gene approach in BC families	Sanger sequencing	HBOC families negative for <i>BRCA1/2</i> and <i>CHEK2</i> 1100delC	49	1 LOF	0	N/A	

Kurian et al J Clin Oncol. 2014 Jul 1;32(19):2001-9.	USA	Multi-gene panel testing of 42 genes	Agilent SureSelect, MiSeq	HBOC cases (NCCN guidelines)	198 HBOC cases including 174 BC cases, of whom 141 tested negative for <i>BRCA1/2</i>	0 LOF, 8 missense	0		N/A
Castéra et al Eur J Hum Genet. 2014 Nov;22(11):1305-13.	French	Multi-gene panel testing ; 3 different capture design (16 genes, 21 genes, 27 genes) , all including <i>BRIP1</i>	Agilent SureSelect, Illumina GAllx	Consecutive HBOC cases referred to Cancer Genetics Clinics for <i>BRCA1/2</i> testing	708	0	0		N/A
Li et al J Med Genet. 2015 Nov 3. pii: jmedgenet-2015-103452. doi: 10.1136/jmedgenet-2015-103452.	Australian	Multi-gene panel testing of 17 genes; potentially relevant variants genotyped in other family members.	Agilent Target Enrichment kit, Axeq technologies	660 cases from multiple-case BC families (KConFab)	660	9 LOF, 7 missense	-	-	RR 0.47 (95%CI 0.15-1.18) ; HR>1.56 excluded
Aloraifi et al Cancer Genet. 2015 Sep;208(9):455-63.	Multi-ethnic: 10 mutation screening studies on <i>BRIP1</i> ; only 2 studies detected LOF variants.	Meta-analysis on 6 genes performed on studies with high-risk BC cases with matched controls	DHPLC, CSGE, Sanger sequencing	Early onset (<50 yo) or familial BC cases	1,287	10	2,174	2	
Hirotsu et al Mol Genet Genomic Med. 2015 Sep;3(5):459-66.	Japanese	Multi-gene panel testing of 25 DNA repair genes	Ion AmpliSeq, Ion Proton, Life Technologies	155 breast or ovarian cancer cases (94% with family history of BC), including 144 cases negative for <i>BRCA1/2</i>	144	0	0		N/A
Rajkumar et al Asian Pac J Cancer Prev. 2015;16(13):5211-7.	Indian	Multi-gene panel testing of 30 genes	TruSeq Enrichment kit, Illumina HiScan SQ	Family history of BC or early onset cases (<35 yo)	91	0	0		N/A
Lincoln et al . J Mol Diagn. 2015 Sep;17(5):533-44.	USA	Multi-gene panel testing of 29 genes	Agilent SureSelect, MiSeq or HiSeq2500	HBOC cases (NCCN guidelines)	735	1	0		N/A
Aloraifi et al FEBS J. 2015 Sep;282(17):3424-37.	Irish	Multi-gene panel testing of 312 genes.	TruSeq Enrichment kit, Illumina HiSeq	Familal BC cases negative for <i>BRCA1/2</i>	104	0	101	0	
Maxwell et al Genet Med. 2015 Aug;17(8):630-8.	USA	Multi-gene panel testing of 22 genes	Agilent SureSelect, sequencer?	<i>BRCA1/2</i> negative patients with early onset BC (<40 yo)	278	1	0		N/A

Cybulski Cet al Clin Genet. 2015 Oct;88(4):366-70.	Polish	Whole exome sequencing and evaluation of 12 genes	Agilent SureSelect human exome kit v4, HiSeq2000	Familial cases negative for <i>BRCA1</i> , <i>CHEK2</i> and <i>NBS1</i> Polish founder mutation	144	1	0	N/A
Tung et al Cancer. 2015 Jan 1;121(1):25-33.	Multi-ethnic, Ashkenazi pop.	Multi-gene panel testing of 25 genes	RainDance Thunderstorm emulsion PCR, HiSeq2500	Negative <i>BRCA1/2</i> cases tested at Myriad	1781 (multi-ethnic pop) + 377 Ashkenazi Jews	7	0	N/A
Couch et al J Clin Oncol. 2015 Feb 1;33(4):304-11.	12 studies, population from USA, Germany,UK, Finland, Greece	Multi-gene panel testing of 17 genes	Agilent custom capture, HiSeq	TNBC cases unselected for family history of BC or OC	1,824	8	0	N/A